Results from CAR T-cell bb2121 first-in-human trial for R/R MM
The anti-BCMA CAR T-cell therapy bb2121 looks extremely promising in multiple myeloma (MM). Here, Noopur Raje, MD, of Massachusetts General Hospital Cancer Center, Boston, MA, discusses the results of...
Author: VJHemOnc
Added: 07/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 30, 2018 Category: Cancer & Oncology Source Type: podcasts
MMY1001 subgroup: daratumumab-Kd in lenalidomide refractory MM
While there are many clinical trials exploring the effect of various novel agents in combination with lenalidomide-dexamethasone therapy in multiple myeloma (MM), patients who are lenalidomide refract...
Author: VJHemOnc
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
The Importance of MRD
Prof Wee Joo Chng, MD discusses the importance of Minimal Residual Disease (MRD) testing in Multiple Myeloma
Author: WorldMyelomaForum
Added: 07/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 26, 2018 Category: Cancer & Oncology Source Type: podcasts
Kinase inhibitor advances in MM: predictive biomarkers & amp; efficacy of daratumumab
Kinase inhibitors are one of the most successful forms of therapy for hematological malignancies, with further potential due to new advances. Speaking from the 1st European Myeloma Network Meeting (EM...
Author: VJHemOnc
Added: 07/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 26, 2018 Category: Cancer & Oncology Source Type: podcasts
Multiple myeloma subgroups for risk-adapted therapy
The contemporary viewpoint is that multiple myeloma (MM) is a group of separate diseases, rather than just one type of cancer. This has allowed patients to be grouped according to their specific form ...
Author: VJHemOnc
Added: 07/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 26, 2018 Category: Cancer & Oncology Source Type: podcasts
CAR T-cells for mulitple myeloma
In this video, Fabio Malavasi, MD, of the University of Turin, Turin, Italy, discusses immunotherapy in multiple myeloma (MM) from the 1st European Myeloma Network Meeting (EMN) 2018, in Turin, Italy....
Author: VJHemOnc
Added: 07/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 26, 2018 Category: Cancer & Oncology Source Type: podcasts
ASCT remains at the forefront of multiple myeloma therapy
Despite recent advances in drug development, autologous stem cell transplant (ASCT) is still, to date, the most effective treatment for multiple myeloma (MM). Speaking from the 1st European Myeloma Ne...
Author: VJHemOnc
Added: 07/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 26, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel drug delivery method to prevent daratumumab infusion-related reactions in MM
While daratumumab is one of the most effective treatments for multiple myeloma (MM), ~50% of all patients who the drug intravenously develop infusion-related reactions. In this video, Torben Plesner, ...
Author: VJHemOnc
Added: 07/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 25, 2018 Category: Cancer & Oncology Source Type: podcasts
Redundancy of age restrictions for MM treatment
Autologous stem cell transplantation (ASCT) for multiple myeloma (MM) patients has often been capped at 65 years of age. However, Mohamad Mohty, MD, PhD, of the University Pierre & Marie Curie, Pa...
Author: VJHemOnc
Added: 07/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 25, 2018 Category: Cancer & Oncology Source Type: podcasts
Refinements in MM treatment: a dynamic, ever-evolving field
Autologous stem cell transplantation is here to stay for multiple myeloma (MM). However, once a treatment has been developed, there is no reason why it should not be improved. Here, Mohamad Mohty, MD,...
Author: VJHemOnc
Added: 07/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 25, 2018 Category: Cancer & Oncology Source Type: podcasts
MRD-guided treatment in multiple myeloma
Measurable residual disease (MRD) status is a valuable prognostic marker in multiple myeloma (MM), but questions still remain. Speaking from the 1st European Myeloma Network (EMN) Meeting, in Turin, I...
Author: VJHemOnc
Added: 07/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 25, 2018 Category: Cancer & Oncology Source Type: podcasts
Optimizing elderly MM patient treatment
Elderly patients with multiple myeloma (MM) are often denied intensive treatment due to the fear they will not be able to tolerate it. However, Mohamad Mohty, MD, PhD of the University Pierre & Ma...
Author: VJHemOnc
Added: 07/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 25, 2018 Category: Cancer & Oncology Source Type: podcasts
Patient fitness is a better criterion for treatment than age in MM
While it is understandable that elderly patients with multiple myeloma (MM) are generally excluded from more aggressive treatments, Mohamad Mohty, MD, PhD, of University Pierre & Marie Curie, Fran...
Author: VJHemOnc
Added: 07/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 25, 2018 Category: Cancer & Oncology Source Type: podcasts
Thoughts on combination carfilzomib & daratumumab in revlimid-refractory multiple myeloma
Noa Biran, MD, discusses her thoughts on the promising combination of carfilzomib and daratumumab in revlimid-refractory multiple myeloma patients at the 2018 Annual Meeting.
Author: obr
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Combination carfilzomib & daratumumab in revlimid-refractory multiple myeloma
Noa Biran, MD, talks about her thoughts on the promising combination of carfilzomib and daratumumab in revlimid-refractory multiple myeloma patients at the 2018 Annual Meeting.
Author: obr
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
